Jump to content



Recommended Posts

COLORADO: "Bill Would Vaccinate Girls Against Cervical Cancer"

Rocky Mountain News (Denver) (01.30.07):: Bill Scanlon


State legislators have introduced a bill requiring human papillomavirus (HPV) vaccination of girls before they enter middle school. Sen. Suzanne Williams (D-Aurora) and Rep. Mike May (R-Parker) said the vaccine, Gardasil, protects against types of the STD that account for 70 percent of all cervical cancer cases. As with other vaccines, parents could decline their permission for the immunization.


"Hearing the word 'cancer' throws the fear of God in people," said Rep. Dianne Primavera (D-Broomfield), who had cervical cancer that was removed surgically. "I'm for anything we can do to help alleviate cervical cancer."


Gardasil is "a true step forward, and we ought to embrace it," said Jim Martin, executive director of the Colorado Department of Public Health and Environment.


About 90 percent of private insurers will cover Gardasil, which costs about $350, said bill advocates. Medicaid and Children's Health Plan would cover girls from low-income families. Martin is confident his department could access federal funding to cover the vaccine's cost.


The measure, Senate Bill 80, was scheduled for a committee discussion Wednesday.




Link to comment
Share on other sites

  • Replies 959
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

AECSL) CSL secures long-term supply of Helixate FS from Bayer
2 February 2007
Ralph Wragg Australian Business News

Sydney - Friday - February 2: (RWE Aust Business News) - CSL (ASX:CSL) has concluded an agreement with Sanofi-Aventis that facilitates an extension of the arrangements with Bayer for the supply of Helixate FS, CSL Behring's recombinant Factor VIII product.

The previous agreement with Bayer on Helixate FS would have expired in 2009, with the new arrangement securing supply for a further eight years until the end of 2017.

In the last financial year Helixate FS generated revenues of $US340 million.

CSL agreed to pay Sanofi-Aventis the Contingent Payment of $US250m and the Deferred Payment of $US65m earlier than originally agreed when CSL acquired Aventis Behring in 2004.

This agreement with Sanofi-Aventis enabled CSL to independently negotiate with Bayer the sub-licensing terms of certain intellectual property related to recombinant Factor VIII, to secure the long-term supply of Helixate FS and to facilitate the settlement of litigation against Bayer.

CSL also noted that a number of other outstanding matters had also now been resolved.

CSL shares last traded at $68.70.


Market likes it. Trading around $71 http://www.sharescene.com/html/emoticons/smile.gif



Link to comment
Share on other sites

CSL sp is skyrocketing. Would any of you think that it is still a reasonably priced share to purchase, NOW??? when the sp is so high??? Of course to hold for longer time - I am not a trader. There are some brokers recommending buying CSL. Your thoughts and opinions are most welcome. Thank you. http://www.sharescene.com/html/emoticons/icon14.gif
Link to comment
Share on other sites



CSL - reasons for:


Gardasil looks to be exceeding sales expectations.

1st case of bird flu in Britain reported this weekend.

efficient management that seems to methodically work through issues.

Locking up future supplies - Helixate.




blood plasma is priced on the market and swings around a lot

low dividend, high PE, uncertain PEG


the fact that it has achieved a new high for its share price - what has that to do with it? Someone is buying.


But the selloff after its earlier run to $50 then back down to $15 should spook any holder. Like most growth oportunities - be vigilant

Link to comment
Share on other sites

  • 2 weeks later...

Notice a bit of changes on the Share Register around 6% @ good old Tax Haven Institution Fund

Trustee address. Notice some of the larger International Oil Co's now as share holders Thru Trust?

Link to comment
Share on other sites

Plasma deal delivers CSL an R&D winner


* Sean Parnell

* February 17, 2007


AUSTRALIAN biomedical giant CSL has held exclusive rights to domestic blood plasma services for over 50 years, frustrating its overseas rivals and causing headaches in government trade negotiations.

But late last year, as a high-level panel reviewed the monopoly arrangement amid calls for CSL to face competition, the Melbourne-based company struck another lucrative deal with federal health authorities.


Under the terms of the deal, which has remained confidential until now, the National Blood Authority will allow 2 per cent of the blood plasma collected from Australian donors to be siphoned off by CSL for its own research and development purposes.


The timing, and terms, of the deal are extraordinary. The Australian Red Cross Blood Service ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ which collects plasma from donors, sends it to CSL for fractionation, and distributes the end plasma products ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ had failed to meet its collection targets in 2005-06. And yet, despite record demand for products such as intravenous immunoglobulin (IVIg), the NBA has signed away up to 6.6 tonnes of plasma ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ around 6600 litres ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ to help a private company improve its product range.


The fractionation contract alone is worth $138 million to CSL ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ formerly the government-owned Commonwealth Serum Laboratories, but now a $13 billion listed company ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ and its rivals in Europe and the United States argue they could match, if not better, the service provided by CSL.


The latest deal was struck at a time when CSL's rivals still held out hope of the fractionation contract being opened up. The review has since been completed, and they will again be shut out when health ministers meet next month.


Cementing its place as global market leader, and further frustrating its rivals, CSL does not have to pay for the plasma it diverts to research and clinical trials ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ a potential saving of several million dollars.


CSL spokeswoman Rachel David says the company is trying to create a "new-generation IVIg" with improved safety and greater options for clinicians.


Worldwide demand for IVIg, a plasma product used to treat autoimmune and inflammatory conditions, is booming. CSL produces a product called Intragam P for the Australian market using locally-donated plasma. From its overseas plants and foreign donors, CSL is also allowed to import Sandoglobulin NF when domestic supplies are low, competing with Swiss-based Octapharma and its product, Octagam.


Octapharma director Frederic Marguerre is outraged by CSL's latest deal, which he argues is a subsidy in breach of World Trade Organisation rules.


But the NBA, which oversees and administers the blood and plasma supply chain, insists it is not a subsidy, rather an opportunity for CSL to improve healthcare in Australia. A spokeswoman says there is "no net revenue gain" to CSL and, given the plasma is provided by unpaid donors, it would be inappropriate to charge CSL.


David says the only way to conduct clinical trials with the approval of the Therapeutic Goods Administration was to use some of the plasma provided by the Red Cross.


"The TGA said 'you must do a trial with Australian plasma in Australia'," David says. "They would not accept plasma from overseas as it might affect results."


The NBA spokeswoman says the trial products would "for the most part" replace products that would otherwise have been provided by CSL, and there will be "no material net cost to Australian governments or impact on Australian product supply".


CSL will use the trials to take further steps to block the transfer of Creutzfeldt-Jakob disease, and test the intramuscular and subcutaneous administration of immunoglobulin. A higher concentration IVIg will also be trialled, which could mean reduced transfusion time for patients.


CSL is continuing work to increase its yield ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ a particularly important move given Health Minister Tony Abbott wants to reduce imports, even though Australia is struggling to maintain its existing ratio of 18 per cent imports when faced with such high demand.


The NBA is working on new criteria for the use of IVIg. Its general manager, Alison Turner, presented a paper last year which questioned whether IVIg was "clinical flavour or saviour", but forecast the need for more imports in any event.


If the trials lead to new and improved products, the NBA will require CSL to make them available at the same price as its existing products ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ a win for the Australian health system, but another blow to CSL's rivals in a market which will only become more volatile and competitive.





Link to comment
Share on other sites

Great half year earnings of $259 mil after tax and a full year profit upgrade in the outlook to between 500-520 mil.


Strong start from Gardasil rollout.


Remains to be seen how much of the good news was already priced into th SP http://www.sharescene.com/html/emoticons/icon14.gif

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...